William Oh, MD
The use of PARP inhibitors against DNA damage repair (DDR) alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field, according to William K. Oh, MD, in a presentation during the 13th Annual
Interdisciplinary Prostate Cancer Congress®
and Other Genitourinary Malignancies.
... to read the full story